MedPath

Ultragenyx Announces Preliminary 2023 Revenue and 2024 Financial Guidance

Ultragenyx Pharmaceutical Inc. has reported its preliminary unaudited 2023 revenue results, with total revenue ranging between $430 million to $435 million. The company also provided its 2024 revenue guidance, expecting total revenue to be between $500 million to $530 million. Key highlights include significant revenue from Crysvita and Dojolvi, and a year-end 2023 cash balance of approximately $776 million. Ultragenyx anticipates several important clinical milestones in 2024, including advancements in its gene therapy programs and Phase 3 studies for various genetic diseases.

Preliminary 2023 Revenue and 2024 Guidance
  • 2023 Total Revenue: $430 million to $435 million
  • Crysvita Revenue: $325 million to $330 million
  • Dojolvi Revenue: $70 million to $71 million
  • 2024 Total Revenue Guidance: $500 million to $530 million
  • Crysvita Revenue Guidance: $375 million to $400 million
  • Dojolvi Revenue Guidance: $75 million to $80 million
Cash Position and Usage
  • Year-end 2023 Cash Balance: Approximately $776 million
  • 2024 Net Cash Used in Operations Guidance: Less than $400 million
2024 Clinical Milestones
  • UX143 (setrusumab) for Osteogenesis Imperfecta (OI): Phase 3 portion of Orbit study expected to be fully enrolled in the first quarter of 2024.
  • GTX-102 for Angelman Syndrome: Phase 1/2 fully enrolled; expansion data expected in the first half of 2024.
  • UX701 for Wilson Disease: Interim Stage 1 data expected in the first half of 2024.
  • UX111 for Sanfilippo syndrome (MPS IIIA): Updated data from pivotal Transfer A study to be presented at WORLDSymposium™ in February 2024.
  • DTX401 for Glycogen Storage Disease Type Ia (GSDIa): Phase 3 data readout expected in the first half of 2024.
  • DTX301 for Ornithine Transcarbamylase (OTC) Deficiency: Phase 3 study dosing patients; expect enrollment to be completed in the first half of 2024.
Ultragenyx is focused on the development and commercialization of novel products for serious rare and ultrarare genetic diseases. The company anticipates 2024 to be a year of significant momentum, with clinical catalysts across multiple value-driving programs and meaningful revenue growth from its commercial products.
Subscribe Icon

Stay Updated with Our Daily Newsletter

Get the latest pharmaceutical insights, research highlights, and industry updates delivered to your inbox every day.

Related Topics

Karyopharm's Selinexor Shows Promise in Myelofibrosis, Phase 3 Data Expected in 2H 2025

Karyopharm Therapeutics anticipates top-line results from its Phase 3 SENTRY trial of selinexor plus ruxolitinib for JAKi-naïve myelofibrosis in the second half of 2025.
The SENTRY trial updated its co-primary endpoint to absolute mean change in total symptom score (Abs-TSS) and increased the sample size to 350 patients.

Ultragenyx Announces Positive 2024 Revenue and Advances Rare Disease Pipeline

Ultragenyx reported preliminary 2024 revenue of $555 million to $560 million, exceeding previous guidance, driven by strong sales of Crysvita and Dojolvi.
The company anticipates total revenue between $640 million and $670 million in 2025, projecting continued growth and pipeline advancement.

Unicycive's OLC Receives FDA Acceptance for Hyperphosphatemia Treatment

Unicycive's New Drug Application for oxylanthanum carbonate (OLC) has been accepted by the FDA, with a PDUFA target action date set for June 28, 2025.
Clinical trial data indicates OLC's potential as a preferred treatment option, with 79% of patients favoring it over previous phosphate binders.

UroGen's UGN-102 Receives FDA Acceptance for Bladder Cancer Treatment

UroGen Pharma's New Drug Application for UGN-102 has been accepted by the FDA, with a PDUFA target action date set for June 13, 2025.
UGN-102 is intended for the treatment of low-grade intermediate-risk non-muscle invasive bladder cancer (LG-IR-NMIBC).

UroGen's UGN-102 Shows Promise for Non-Muscle Invasive Bladder Cancer

UroGen's New Drug Application for UGN-102 has been accepted by the FDA, with a PDUFA target action date set for June 13, 2025.
Phase 3 ENVISION trial data showed a 79.6% complete response rate at three months and an 82.3% duration of response at 12 months with UGN-102.

Ultragenyx Reports Positive Q3 2024 Results and Clinical Updates

Ultragenyx's Q3 2024 total revenue increased by 42% year-over-year to $139 million, driven by Crysvita and Dojolvi sales growth, reaffirming its 2024 revenue guidance of $530-$550 million.
The FDA granted Breakthrough Therapy Designation for setrusumab (UX143) in osteogenesis imperfecta, based on promising Phase 2 clinical trial results showing a significant reduction in fracture rate.

UNITY Biotechnology's UBX1325 Shows Promise in Diabetic Macular Edema Treatment

UNITY Biotechnology's UBX1325 (foselutoclax) targets senescent cells in diabetic macular edema (DME), offering a novel approach to address limitations of current anti-VEGF therapies.
A Phase 2b ASPIRE study is underway, comparing UBX1325 to aflibercept, with topline 24-week primary endpoint data expected in Q1 2025 and 36-week data in Q2 2025.

UNITY Biotechnology's UBX1325 for DME Advances with FDA Guidance on Pivotal Trial Design

UNITY Biotechnology received FDA guidance suggesting a non-inferiority trial design for UBX1325 (foselutoclax) compared to aflibercept in treating diabetic macular edema (DME).
The pivotal study's primary endpoint is expected to be best-corrected visual acuity (BCVA) assessed by the ETDRS scale, with a non-inferiority margin of 4 letters.

UNITY Biotechnology's UBX1325 Pivotal Trial Design for Diabetic Macular Edema

UNITY Biotechnology's UBX1325 (foselutoclax) is under development as a novel senolytic therapeutic for diabetic macular edema (DME).
A pivotal study design, based on FDA interaction, will compare UBX1325 to aflibercept, focusing on non-inferiority in best-corrected visual acuity (BCVA).

Karyopharm Announces Preliminary Unaudited 2023 Revenue and 2024 Objectives

Karyopharm Therapeutics Inc. revealed its preliminary unaudited financial results for 2023, including total revenue and U.S. XPOVIO net product revenue, and outlined its strategic objectives for 2024, focusing on advancing its pipeline in multiple myeloma, endometrial cancer, and myelofibrosis.

Reference News

[1]
Ultragenyx Reports Preliminary 2023 Revenue; Guidance for
globenewswire.com · Jan 7, 2024

Ultragenyx reported 2023 preliminary revenues: $430-$435M total, $325-$330M from Crysvita, $70-$71M from Dojolvi, with a...

© Copyright 2025. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy